Advertisement

Kutane Lymphome beim alten und geriatrischen Patienten

  • Jan P. Nicolay
  • Sergij Goerdt
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Kutane Lymphome sind überwiegend Erkrankungen des älteren und alten Menschen. Ihr Management erfordert eine stadiengerechte Therapie, d. h. frühe Stadien und indolente Formen können im allgemeinen mit lokalen Therapien behandelt werden, während spätere Stadien und aggressivere Varianten eine systemische Therapie erfordern. Explizite Therapieempfehlungen speziell für geriatrische Patienten existieren auf Grund der Seltenheit der Erkrankung und mangelnde durch vergleichende Studien belegte Evidenz nicht. Dabei besteht gerade für diese Patientengruppe ein erhöhtes Risiko, da ein hohes Alter einen negativen prognostischen Marker für kutane T-Zell-Lymphome darstellt und sich aggressivere B-Zell-Lymphome auch fast ausschließlich bei hochbetagten Patienten entwickeln. Trotz mangelnder altersspezifischer Therapieempfehlung muss die Therapieentscheidung bei geriatrischen Patienten häufig sehr individuell getroffen werden, da viele Kontraindikationen und Komorbiditäten speziell im höheren Patientenalter das Erstlinientherapiespektrum einschränken und ein Ausweichen auf alternative Optionen notwendig machen.

Literatur

  1. Amber KT, Bloom R, Nouri K (2016) Second primary malignancies in CTCL patients from 1992 to 2011: a SEER-based, population-based study evaluating time from CTCL diagnosis, age, sex, stage, and CD30+ subtype. Am J Clin Dermatol 17:71–77CrossRefPubMedGoogle Scholar
  2. Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R et al (2015) Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma 2016 Aug 57(8):1823–1830Google Scholar
  3. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261–266CrossRefPubMedGoogle Scholar
  4. Bessell EM, Humber CE, O’Connor S, English JS, Perkins W, Dickinson PD, Patel AN (2012) Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification. Br J Dermatol 167:1118–1123CrossRefPubMedGoogle Scholar
  5. Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115:155–162CrossRefPubMedGoogle Scholar
  6. DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, Guenova E (2015) Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol 27:128–133CrossRefPubMedGoogle Scholar
  7. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C (2010) Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28:2365–2372CrossRefPubMedGoogle Scholar
  8. Eder J, Kern A, Moser J, Kitzwogerer M, Sedivy R, Trautinger F (2015) Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. J Eur Acad Dermatol Venereol 29:1517–1523CrossRefPubMedGoogle Scholar
  9. Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkotter C et al (2015) Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 93:1077–1086CrossRefPubMedGoogle Scholar
  10. Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M et al (2014) Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol 93:129–136CrossRefPubMedGoogle Scholar
  11. Feenstra J, Grobbee DE, Remme WJ, Stricker BH (1999) Drug-induced heart failure. J Am Coll Cardiol 33:1152–1162CrossRefPubMedGoogle Scholar
  12. Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S, Delaporte E, Dereure O, Bachelez H, Vergier B et al (2009) Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 145:329–330PubMedGoogle Scholar
  13. Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D’Incan M, Ram-Wolff C, Dalac S et al (2014) Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 150:535–541CrossRefPubMedGoogle Scholar
  14. Heumann TR, Esiashvili N, Parker S, Switchenko JM, Dhabbaan A, Goodman M, Lechowicz MJ, Flowers CR, Khan MK (2015) Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique. Int J Radiat Oncol Biol Phys 92:183–191CrossRefPubMedPubMedCentralGoogle Scholar
  15. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M et al (2015) Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72:286–292CrossRefPubMedGoogle Scholar
  16. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y et al (2015) Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26:2490–2495PubMedPubMedCentralGoogle Scholar
  17. Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 125:71–81CrossRefPubMedGoogle Scholar
  18. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 70:223 e1–223 e17; quiz 240–222CrossRefGoogle Scholar
  19. Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, Specht L (2012) Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 166:399–404CrossRefPubMedGoogle Scholar
  20. Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP (2005) Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2:53–57CrossRefPubMedGoogle Scholar
  21. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:479–484CrossRefPubMedGoogle Scholar
  22. Korgavkar K, Weinstock MA (2014) Changing incidence trends of cutaneous B-cell lymphoma. J Invest Dermatol 134:840–842CrossRefPubMedGoogle Scholar
  23. Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D et al (2015) Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 4:1440–1447CrossRefPubMedPubMedCentralGoogle Scholar
  24. Massone C, Fink-Puches R, Wolf I, Zalaudek I, Cerroni L (2015) Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type. J Am Acad Dermatol 72:1016–1020CrossRefPubMedGoogle Scholar
  25. Nicolay JP, Klemke CD (2014) Management of cutaneous lymphomas. Hautarzt 65:607–613CrossRefPubMedGoogle Scholar
  26. Nicolay JP, Muller-Decker K, Schroeder A, Brechmann M, Mobs M, Geraud C, Assaf C, Goerdt S, Krammer PH, Gulow K (2016) Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NFkappaB. Blood 128:805CrossRefPubMedPubMedCentralGoogle Scholar
  27. Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31:2103–2109CrossRefPubMedGoogle Scholar
  28. Oka T, Sugaya M, Cury-Martins J, Vasconcelos-Berg R, Suga H, Miyagaki T, Scheinberg P, Fujita H, Izutsu K, Sato S et al (2016) Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: summary of 11 cases from two facilities in Japan and Brazil. J Dermatol 43:638–642CrossRefPubMedGoogle Scholar
  29. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S et al (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713–1722CrossRefPubMedGoogle Scholar
  30. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients With Sezary syndrome. Clin Lymphoma Myeloma Leuk 15:e83–e93CrossRefPubMedGoogle Scholar
  31. Prince HM, Whittaker S, Hoppe RT (2009) How I treat mycosis fungoides and Sezary syndrome. Blood 114:4337–4353CrossRefPubMedGoogle Scholar
  32. Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF (2014) Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Ann Hematol 93:333–334CrossRefPubMedGoogle Scholar
  33. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A et al (2015) Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33:3766–3773CrossRefPubMedPubMedCentralGoogle Scholar
  34. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609CrossRefPubMedGoogle Scholar
  35. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM et al (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71:327–349CrossRefPubMedPubMedCentralGoogle Scholar
  36. Sonnenblick M, Rosin A (1991) Cardiotoxicity of interferon. A review of 44 cases. Chest 99:557–561CrossRefPubMedGoogle Scholar
  37. Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, Sterry W (2013) Brief S2k guidelines – cutaneous lymphomas. J Dtsch Dermatol Ges: J Ger Soc Dermatol: JDDG 11(Suppl 3):19–28, 20–30CrossRefGoogle Scholar
  38. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentralGoogle Scholar
  39. Thieblemont C, Coiffier B (2007) Lymphoma in older patients. J Clin Oncol 25:1916–1923CrossRefPubMedGoogle Scholar
  40. Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93:403–409CrossRefPubMedGoogle Scholar
  41. Wilson LD, Hinds GA, Yu JB (2012) Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 12:291–296CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin MannheimMannheimDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations